Association of weekly or biweekly use of 50 000 IU vitamin D3 with hypervitaminosis D

4Citations
Citations of this article
34Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Since the beginning of the COVID-19 pandemic, many Iranian people have been taking 50 000 IU of vitamin D3 on weekly or biweekly bases in order to enhance their immune system function. This cross-sectional study was conducted on the patients of endocrinology clinic to compare 25(OH)D levels of weekly or biweekly consumption with the monthly users of vitamin D3 50 000 IU. The level >100 ng/mL of 25(OH)D was defined as hypervitaminosis D. In total, 211 patients (108 and 103 patients in monthly and weekly/biweekly groups, respectively) were studied. In the subgroups of weekly and biweekly users, the rates of hypervitaminosis were 18.9% and 4.5%, respectively. In contrast, only 0.9% of monthly users had hypervitaminosis D. The highest vitamin D value of 185 ng/mL was detected in a patient who had consumed 50 000 IU vitamin D3 weekly for 6 years. No hypercalcaemia was detected in patients with hypervitaminosis D.

Cite

CITATION STYLE

APA

Hashemipour, S., Ghobadi, A., Hadizadeh Khairkhah, S. M. R., Ranjbaran, M., Badri, M., Ghafelehbashi, S. H., & Gheraati, M. (2022). Association of weekly or biweekly use of 50 000 IU vitamin D3 with hypervitaminosis D. British Journal of Clinical Pharmacology, 88(7), 3506–3509. https://doi.org/10.1111/bcp.15186

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free